Skip to content
The Intraday Markets
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

MRK Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

MRK
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

MRK Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

MRK

$134.66
$-0.89 (-0.65%)-0.65%
Open
Loading chart...
IndexN/A
Market Cap332.59B
Enterprise Value299.33B
Income$5.08B
Sales$15.53B
Employees73,000
P/E41.95
P/S4.06
P/B5.01
P/C21.31
EV/EBITDA10.59
EV/Sales13.48
EPS (ttm)3.21
Earnings2025-10-30
Gross Margin81.92%
Oper. Margin35.13%
Profit Margin28.01%
Volume2.24M
Shs Outstand2.47B
Change-0.65%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTD2.24%
Perf Year11.14%
Perf 3Y-1.47%
Perf 5Y37.20%
Perf 10Y122.33%
IPO1978-01-13
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue$64.17B$60.12B$59.28B$48.70B$41.52B$39.12B$42.29B$40.12B
Cost of Revenue$15.19B$16.13B$17.41B$13.63B$13.62B$12.02B$13.51B$12.91B
Gross Profit$48.98B$43.99B$41.87B$35.08B$27.90B$27.11B$28.79B$27.21B
Gross Margin76.32%73.17%70.63%72.02%67.20%69.29%68.06%67.82%
Operating Expenses$28.75B$41.03B$23.59B$21.88B$22.35B$19.18B$19.85B$20.41B
Operating Income$20.22B$2.95B$18.28B$13.20B$5.55B$7.93B$8.93B$6.80B
Operating Margin31.51%4.91%30.84%27.10%13.36%20.26%21.12%16.94%
Net Income$17.12B$365.00M$14.52B$13.05B$7.07B$9.84B$6.22B$2.39B
Net Margin26.68%0.61%24.49%26.79%17.02%25.16%14.71%5.97%
EPS (Basic)$6.76$0.14$5.73$5.16$2.79$3.84$2.40$0.95
EBITDA$25.71B$6.91B$21.32B$17.90B$10.18B$11.37B$13.99B$11.95B
Stock Option Compensation Expense$761.00M$645.00M$541.00M$479.00M$441.00M$417.00M$348.00M$312.00M
Price To Earnings Ratio14.72778.7119.3514.8627.9222.6030.3760.43
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market Capitalization$251.88B$284.23B$280.93B$193.90B$197.34B$222.44B$188.89B$144.67B
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$117.11B$106.67B$109.16B$105.69B$91.59B$84.40B$82.64B$87.87B
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$70.73B$69.04B$63.10B$67.44B$66.18B$58.40B$55.76B$53.30B
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$46.31B$37.58B$45.99B$38.18B$25.32B$25.91B$26.70B$34.34B
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$46.31B$37.58B$45.99B$38.18B$25.32B$25.91B$26.70B$34.34B
Total Liabilities & Stockholders Equity$117.11B$106.67B$109.16B$105.69B$91.59B$84.40B$82.64B$87.87B
Book Value Per Share$18.31$14.44$18.19$15.12$10.04$10.14$10.37$12.82
Tangible Book Value Per Share$3.29$-0.60$1.81$-2.35$-3.00$-2.97$-1.73$0.78
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on Assets14.62%0.34%13.30%12.35%7.72%11.66%7.53%2.72%
Return on Equity36.96%0.97%31.57%34.17%27.91%37.99%23.30%6.97%
Return on Invested Capital18.97%0.71%18.53%13.90%6.03%9.42%9.67%3.49%
Quick Ratio1.151.001.231.020.810.970.921.06
Current Ratio1.361.251.471.271.021.241.171.33
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Net Income$17.12B$365.00M$14.52B$13.05B$7.07B$9.84B$6.22B$2.39B
Depreciation$4.50B$3.87B$3.91B$3.21B$3.49B$3.31B$4.52B$4.68B
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$21.47B$13.01B$19.09B$14.11B$10.25B$13.44B$10.92B$6.45B
Capital Expenditures$3.37B$3.86B$4.39B$4.45B$4.68B$3.47B$2.62B$1.89B
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends Paid$7.84B$7.45B$7.01B$6.61B$6.21B$5.70B$5.17B$5.17B
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref Stock$1.31B$1.35B$0.00$840.00M$1.28B$4.78B$9.09B$4.01B
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash Flow$18.10B$9.14B$14.71B$9.66B$5.57B$9.97B$8.31B$4.56B
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Jul 31 · 2:18PM1 Unstoppable Dividend ETF Up 26% in 2026 to Buy and Hold for the Next 20 YearsThe Motley Fool ↗Jul 28 · 10:30AMPrediction: This Dividend ETF Will Thrive After 20 Years No Matter What the Market DoesThe Motley Fool ↗Jul 27 · 8:02PMAfter Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?The Motley Fool ↗Jul 26 · 11:30PMAscentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026GlobeNewswire Inc. ↗Jul 26 · 12:30PMIf I Were Starting My Portfolio From Scratch Today, This Is the First ETF I'd BuyThe Motley Fool ↗Jul 24 · 4:30AM2 Top Growth Stocks to Buy Right Now Without Any HesitationThe Motley Fool ↗Jul 22 · 8:33PMWhich ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?The Motley Fool ↗Jul 22 · 3:23PMWant Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.The Motley Fool ↗
Show 12 more stories↓
Jul 21 · 5:00PMPD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsightGlobeNewswire Inc. ↗Jul 21 · 5:00PMCorrection: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobeNewswire Inc. ↗Jul 15 · 3:00PMAutoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS InsiderGlobeNewswire Inc. ↗Jul 15 · 12:00PMSlate Medicines Strengthens Board of Directors with Appointment of Mark W. HahnGlobeNewswire Inc. ↗Jul 15 · 8:15AMOral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments AcceleratesGlobeNewswire Inc. ↗Jul 13 · 5:00PMHead and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobeNewswire Inc. ↗Jul 13 · 5:00PMCosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in GreeceGlobeNewswire Inc. ↗Jul 9 · 12:15PMVanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?The Motley Fool ↗Jul 8 · 11:28AMBBH vs. XPH: Which Healthcare ETF Is Better for Beginners?The Motley Fool ↗Jul 7 · 9:30AMThe Dividend ETF Quietly Outperforming the S&P 500The Motley Fool ↗Jul 7 · 9:15AMModerna Stock Is Soaring. Is It Too Late to Buy?The Motley Fool ↗Jul 5 · 9:20PM3 Dividend ETF Picks That Could Build Serious Long-Term WealthThe Motley Fool ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
CHIRFI GUINDO
Sell
10.0K
$135.00
$1.4M
Aug 13, 26
Guindo Chirfi
Sell
10.0K
$135.00
$1.4M
Aug 13, 26
Zachary Jennifer
Option
13.4K
$84.71
$1.1M
Aug 12, 26
JENNIFER L ZACHARY
Sell
80.3K
$133.46
$10.7M
Aug 12, 26
RICHARD ROBERT DELUCA JR
Sell
11.7K
$131.63
$1.5M
Aug 12, 26

Company

CEO: Robert DavisEmployees: 74000www.merck.com
About the company↓

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Discover more

You may be interested in
ADBE

Adobe Inc

$264.19

↓ 2.31%
AMD

Advanced Micro Devices

$501.45

↑ 3.84%
JPM

JPMorgan Chase & Co

$362.84

↓ 0.08%
PYPL

PayPal Holdings Inc

$59.89

↓ 1.12%
META

Meta Platforms Inc

$591.53

↓ 0.56%
MSFT

Microsoft Corp

$496.75

↑ 0.01%
ORCL

Oracle Corp

$151.96

↓ 2.69%
ABX

Abacus Global Management Inc

$9.37

↑ 9.98%
BAC

Bank of America Corp

$64.50

↑ 0.63%
MA

Mastercard Inc

$567.67

↑ 0.11%
CRM

Salesforce Inc

$196.64

↓ 2.32%
NVDA

NVIDIA Corp

$225.07

↓ 0.08%
The Intraday Markets

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC

Why it moved over time

Catalyst history

5 entries
Aug 13, 2026
Legal+0.11%

Merck & Co. said the FDA accepted an sBLA for ENFLONSIA to expand RSV indication to high-risk children under two, a regulatory step that could broaden pediatric use and revenue.

Key fact: FDA accepted supplemental BLA for ENFLONSIA to include prevention of RSV LRTD in children under two at increased risk.

businesswire.com: U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season↗
Aug 6, 2026
Earnings+0.25%

Merck's Q2 beat on revenue and narrowed-and-raised 2026 sales outlook after $16.6 billion revenue and pipeline/launch gains, signaling stronger near-term growth despite acquisition-related charges.

Key fact: Q2 revenue $16.6 billion and company raised and narrowed its 2026 sales outlook.

zacks.com: MRK Q2 Earnings Call Puts Pipeline Progress in Focus↗
Aug 5, 2026
Product-1.90%

Merck's presentation of Phase III data for a once-weekly oral HIV treatment and plans for a monthly oral PrEP at the International AIDS Conference highlighted a potential $5B market opportunity.

Key fact: Presented Phase III results for a once-weekly oral HIV regimen and outlined a monthly oral PrEP candidate, cited as a ~$5 billion growth opportunity.

seekingalpha.com: Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference Transcript↗
Show 2 earlier catalysts↓
Aug 4, 2026
Product-1.90%

Merck presented Phase III data for a once-weekly oral HIV regimen and a monthly oral PrEP candidate at the International AIDS Conference, offering new clinical readthroughs for a potential $5B growth opportunity.

Key fact: Presented Phase III data for a once-weekly oral HIV regimen and highlighted a monthly oral PrEP as a $5 billion growth opportunity.

seekingalpha.com: Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference Transcript↗
Aug 3, 2026
Earnings+0.33%

Merck is in focus ahead of its Aug. 4 pre-market Q2 earnings report, as investors weigh consensus revenue and EPS estimates and updates on Keytruda lifecycle extensions and pipeline developments.

Key fact: Merck will report Q2 results Aug. 4 before the open; Zacks consensus sales $16.33 billion and EPS estimate of a $0.26 loss.

defenseworld.net: Merck & Co., Inc. $MRK Shares Bought by Argent Capital Management LLC↗